logo-loader

ANGLE developing an assay which may revolutionise lung cancer treatment

Published: 08:04 22 Sep 2021 BST

ANGLE PLC -

ANGLE PLC (AIM:AGL, OTCQX:ANPCY, FRA:DWV) said it has made substantial progress developing an assay that helps doctors decide whether patients with non-small cell lung cancer will respond to a class of drugs called immune checkpoint inhibitors.

The PD-L1 test will focus on the capabilities of the Parsortix liquid biopsy system, which has the ability to isolate circulating tumour cells of various types and assess for likely beneficiaries of the treatment regimen.

The alternative to a blood draw and analysis of the type being mooted by ANGLE is an invasive and dangerous tumour tissue biopsy.

The work is part of a collaboration with the Health Research Institute of Santiago, Spain, which recently published results of a study in patients with metastatic non-small cell lung cancer undergoing treatment with the immune checkpoint inhibitor, pembrolizumab.

Chief executive, Andrew Newland, said: "ANGLE is pleased to see continued efforts being made to better identify patients who will respond well to immune checkpoint inhibitors.

“Whilst ICIs have revolutionised metastatic non-small cell lung cancer patient care, they are costly and associated with significant side effects.

“We have made substantial progress in the development of our Parsortix-based PD-L1 assay and are offering this to our pharma services customers.

“In addition, we are planning to investigate its utility in guiding immunotherapy treatments with the aim of offering the assay as a laboratory-developed test from our clinical laboratories for patient management.”

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24